1. Home
  2. JDZG vs MEIP Comparison

JDZG vs MEIP Comparison

Compare JDZG & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JDZG
  • MEIP
  • Stock Information
  • Founded
  • JDZG 2020
  • MEIP 2000
  • Country
  • JDZG China
  • MEIP United States
  • Employees
  • JDZG N/A
  • MEIP N/A
  • Industry
  • JDZG Other Consumer Services
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • JDZG Real Estate
  • MEIP Health Care
  • Exchange
  • JDZG Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • JDZG 15.2M
  • MEIP 16.3M
  • IPO Year
  • JDZG 2024
  • MEIP 2003
  • Fundamental
  • Price
  • JDZG $0.70
  • MEIP $2.79
  • Analyst Decision
  • JDZG
  • MEIP Hold
  • Analyst Count
  • JDZG 0
  • MEIP 2
  • Target Price
  • JDZG N/A
  • MEIP $7.00
  • AVG Volume (30 Days)
  • JDZG 779.8K
  • MEIP 11.7K
  • Earning Date
  • JDZG 11-27-2024
  • MEIP 02-11-2025
  • Dividend Yield
  • JDZG N/A
  • MEIP N/A
  • EPS Growth
  • JDZG N/A
  • MEIP N/A
  • EPS
  • JDZG 0.06
  • MEIP N/A
  • Revenue
  • JDZG $2,334,771.00
  • MEIP N/A
  • Revenue This Year
  • JDZG N/A
  • MEIP N/A
  • Revenue Next Year
  • JDZG N/A
  • MEIP N/A
  • P/E Ratio
  • JDZG $11.93
  • MEIP N/A
  • Revenue Growth
  • JDZG 52.08
  • MEIP 33.76
  • 52 Week Low
  • JDZG $0.45
  • MEIP $2.30
  • 52 Week High
  • JDZG $15.08
  • MEIP $4.97
  • Technical
  • Relative Strength Index (RSI)
  • JDZG N/A
  • MEIP 50.43
  • Support Level
  • JDZG N/A
  • MEIP $2.64
  • Resistance Level
  • JDZG N/A
  • MEIP $2.91
  • Average True Range (ATR)
  • JDZG 0.00
  • MEIP 0.12
  • MACD
  • JDZG 0.00
  • MEIP 0.00
  • Stochastic Oscillator
  • JDZG 0.00
  • MEIP 46.43

About JDZG JIADE LIMITED Common stock

Jiade Ltd Ltd is engaged in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platforms and auxiliary solutions. The Group offers pre-enrollment guidance on school/selection and application development, training for entrance exams, and assistance in the application process. The Group also offers offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance in the People's Republic of China.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: